SAROGLITAZAR MAGNESIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C25H28NO4S.Mg
Molecular Weight	901.423
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Mg++].CCO[C@@H](CC1=CC=C(OCCN2C(C)=CC=C2C3=CC=C(SC)C=C3)C=C1)C([O-])=O.CCO[C@@H](CC4=CC=C(OCCN5C(C)=CC=C5C6=CC=C(SC)C=C6)C=C4)C([O-])=O

InChI

InChIKey=UJYFZCVPOSZDMK-YPPDDXJESA-L

InChI=1S/2C25H29NO4S.Mg/c2*1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20;/h2*5-14,24H,4,15-17H2,1-3H3,(H,27,28);/q;;+2/p-2/t2*24-;/m00./s1

HIDE SMILES / InChI

Description
Sources: https://timesofindia.indiatimes.com/business/india-business/Zydus-Group-launches-new-diabetic-drug/articleshow/20459662.cms | https://www.ncbi.nlm.nih.gov/pubmed/25674933 | https://clinicaltrials.gov/ct2/show/NCT03112681 | https://clinicaltrials.gov/ct2/show/NCT03863574

Saroglitazar, a dual peroxisome proliferator-activated receptor PPAR-α/γ agonist, was an emerging therapeutic option on glycemic and lipid parameters. The Zydus Group has launched LipaglynTM ((Saroglitazar) in India for diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In addition, saroglitazar participated in phase II clinical trials that completed enrolment in patients with primary biliary cholangitis and in patients with non-alcoholic steatohepatitis.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Peroxisome proliferator-activated receptor alpha 62 Target ID: CHEMBL239 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26171220 \| https://www.drugdevelopment-technology.com/projects/lipaglyn-saroglitazar-treating-type-ii-diabetes/	Agonist 2678		0.65 pM [EC50]
Peroxisome proliferator-activated receptor gamma 111 Target ID: CHEMBL235 Sources: https://www.drugdevelopment-technology.com/projects/lipaglyn-saroglitazar-treating-type-ii-diabetes/ \| https://www.ncbi.nlm.nih.gov/pubmed/26171220	Agonist 2678		3.0 nM [EC50]

PubMed

Title	Date	PubMed
Saroglitazar for the treatment of dyslipidemia in diabetic patients.	2015 Mar	25674933
Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.	2018 Dec	29224415
Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.	2018 Jun	29164820

Patents

Sample Use Guides

In Vivo Use Guide

Primary Biliary Cirrhosis: saroglitazar magnesium 2 mg or 4 mg tablet Once daily for 16 weeks Non Alcoholic Steatohepatitis: Saroglitazar Magnesium 2 mg or 4 mg tablet orally once daily in the morning before breakfast for 24 weeks.

Route of Administration: Oral

Name

Type

Language

SAROGLITAZAR MAGNESIUM

Common Name

English

MAGNESIUM, BIS((.ALPHA.S)-.ALPHA.-(ETHOXY-.KAPPA.O)-4-(2-(2-METHYL-5-(4-(METHYLTHIO)PHENYL)-1H-PYRROL-1-YL)ETHOXY)BENZENEPROPANOATO-.KAPPA.O)-, (T-4)-

Systematic Name

English

LIPAGLYN

Brand Name

English

(2S)-2-ETHOXY-3-(4-(2-(2-METHYL-5-(4-(METHYLSULFANYL)PHENYL)-1H-PYRROL-1-YL(ETHOXY)PHENYL)PROPANOIC ACID, MAGNESIUM SALT (2:1)

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

686819